AgaMatrix Holdings Announces Corporate Name Change and New CEO Rick Valencia, and Bayer Commercial Partnership in China
In support of their continued expansion into the global diabetes device market, AgaMatrix Holdings, LLC announces a corporate name change to WaveForm Diabetes to reflect their commitment to diabetes care, led by new Executive Chairman and CEO, Rick Valencia
Salem, NH, June 1, 2020 – The newly named WaveForm Diabetes (formerly AgaMatrix Holdings) welcomes new Executive Chairman and CEO, Rick Valencia, to further the company’s growth and expansion into global markets.
Mr. Valencia has extensive experience in digital health and diabetes care, serving as a Board Member at Tandem Diabetes, and Executive Chairman at TrekIT Health. Previously, Mr. Valencia founded and served as the President of Qualcomm Life, Inc., a digital health pioneer. Qualcomm Life enabled remote patient monitoring by connecting medical monitoring and diagnostic devices and combining the data to provide meaningful insights to patients and their caregivers.
“I am honored and excited to join the WaveForm Diabetes team during this pivotal stage in the company and the explosive growth in the diabetes care industry, said Mr. Valencia. WaveForm has a 20-year track record of delivering high quality, connected glucose management solutions to market in partnership with some of the world’s leading diabetes and retail pharmacy brands. Their new, disruptive, continuous glucose monitor is a game changer that, at a time when diabetes continues to grow at an alarming rate around the world, will help to ensure more people living with diabetes have access to easy to use, affordable, yet state-of-the-art glucose management solutions.”
In addition to the new name and new leadership, Waveform Diabetes announced that it has entered into a commercial agreement with Bayer, the global life science enterprise, to provide innovative continuous glucose monitoring (CGM) solutions that help address unmet needs for patients in China. Under the new partnership with Bayer, WaveForm will develop a 15-day wear CGM while Bayer will be responsible for the commercialization, distribution, sales, and customer support in mainland China. WaveForm and Bayer will explore customized enhancements to the CGM to meet the needs of Chinese patients and physicians.
“We are excited to work with Bayer to bring a new glucose monitoring solution that will provide the benefits of extended wear time and virtually pain-free insertion, with the real-time data and alerts of a fully-featured CGM, said John Alberico, former CEO of AgaMatrix, Inc who will be staying with the company as President, COO and member of the Board of Directors. Leveraging the expertise and leadership that Bayer has established in diabetes management, we will deliver more benefits for patients in China.”
According to the latest figures from the International Diabetes Federation,1 an estimated 116 million people aged 20 years and older are living with diabetes in China, and this figure is anticipated to grow to 140 million people over the next 10 years.
More information about the Bayer partnership can be found at:
The WaveForm CGM is based on several pioneering, patented innovations in glucose sensor technology, facilitating a virtually pain-free insertion process, limited interferences, extended wear time, and environmentally friendly, reusable parts. The system consists of a thin, wearable sensor that collects glucose data from just below the skin which is processed and wirelessly transferred to a mobile app through a small transmitter. The rechargeable transmitter lasts an entire session on one complete charge, and uses Bluetooth® wireless technology to transfer data to an Android and iOS compatible mobile app.
WaveForm received CE Mark approval for their 14-day CGM system in November 2019, and began commercial activities to release the product under the GlucoMen Day brand in select European countries through their partnership with A. Menarini Diagnostics S.r.l. WaveForm is preparing for clinical studies in both mainland China and the United States, and also continues to conduct studies for extended sensor wear-time and alternate site indications within Europe.
1 International Diabetes Federation. IDF Diabetes Atlas, 9th edition. Brussels, Belgium: International Diabetes Federation, 2019.
About WaveForm Diabetes (formerly AgaMatrix Holdings, LLC)
WaveForm Diabetes is a holding company for two businesses that develop novel and proprietary technologies for diabetes care, AgaMatrix Inc. and WaveForm Technologies, Inc.
WaveForm Technologies, Inc. discovers and develops novel and proprietary new technologies for diabetes care. WaveForm’s products under development include innovative continuous glucose monitoring sensor technology, related firmware, software and data storage platforms. WaveForm is also developing a proprietary “closed loop” insulin delivery platform designed to provide a complete solution for patients living with diabetes.
AgaMatrix Inc. provides diagnostic technologies for diabetes care, including blood glucose monitoring devices and related firmware, software and data storage solutions. AgaMatrix has developed, manufactured and commercially launched 17 blood glucose monitoring products since the Company’s 2001 inception, and produced over 8 million blood glucose monitors and over 3 billion test strips. AgaMatrix Inc. owns and operates manufacturing and engineering facilities in Salem, NH USA and in Guangdong Province, China.
Forward-Looking Statements and Historical Financial References
This press release contains forward-looking statements, which provide our current expectations or forecasts of future events. Forward-looking statements include, without limitation:
- information concerning possible or assumed future operations, business plans, product development plans or financial results for WaveForm Diabetes and WaveForm Technologies, Inc.;
- statements about our potential or prospects for future product sales;
- statements about our future levels of operating expenses, or operating profit or loss;
- statements about our research and product development activities and schedules;
- statements about our future capital requirements and the sufficiency of our cash, cash equivalents, investments and other sources of funds to meet these requirements;
- other statements about our plans, objectives, expectations and intentions; and
- other statements that are not historical fact.
In some cases, you can identify forward-looking statements by words such as “anticipate,” “believe” or “intend,” but the absence of those words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward- looking statements. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons.
You should not unduly rely on these forward-looking statements, which speak only as of the date of this press release. We undertake no obligation to publicly update any forward- looking statements to reflect circumstances or events after the date of this press release, or to reflect the occurrence of unanticipated events.
For Additional Information Contact